| FAMILY/DRUG NAME | MECHANISM | COMPANY | STATUS |
| Interferons - Mimic naturally-occurring, infection-fighting immune substance produced in the body |
Intron A
(Interferon
alfa-2b | Immunomodulator | Merck,
Whitehouse Station, NJ | FDA Approved
1991 |
Pegasys
(Peginterferon alfa-2a) | Immunomodulator | Genentech,
South SanFrancisco, CA | FDA Approved 2005 |
| There are other brands of interferon approved for HCV treatment, but they have not been FDA-approved for HBV: Wellferon (Glaxo), Roferon(Hoffman-La Roche), and Infergen (Amgen) |
| Nucleoside Analogues - Interfere with the viral DNA polymerase enzyme used for hepatitis B virus reproduction |
Epivir-HBV
(Lamivudine) | Inhibits viral DNA polymerase | GlaxoSmithKline Philadelphia, PA | FDA Approved
1998 |
Hepsera
(Adefovir Dipivoxil) | Inhibits viral DNA polymerase | Gilead
Foster City, CA | FDA Approved
2002 |
Baraclude
(Entecavir) | Inhibits viral DNA polymerase | Bristol-Myers SquibbPrinceton, NJ | FDA Approved
2005
|
Tyzeka
Sebivo (Europe)
(Telbivudine) | Inhibits viral DNA polymerase | Novartis,
Switzerland | FDA Approved
2006 |
Viread
(Tenofovir) | Inhibits viral DNA polymerase | Gilead
Foster City, CA | FDA Approved 2008 |
Clevudine
(L-FMAU)
| Inhibits viral DNA polymerase | Bukwang
South Korea
Eiasai, Japan | Approved S. Korea
2006 (Levovir) |
MIV-210
| Inhibits viral DNA polymerase | Medivir/Daewoong
South Korea | Phase II |
Amdoxovir
(DAPD) | Inhibits viral DNA polymerase | RFS Pharm LLC
Tucker, GA | Phase II |
| AGX-1009 | Prodrug of Tenofovir | Agenix, Australia | Phase I, China |
| Non-Nucleoside Antivirals - Interfere with proteins involved in viral reproduction |
NOV-205
(BAM 205) | Small Molecule | Novelos
Newton, MA | Approved in Russia |
| LB80380 (ANA380) | Inhibits viral RNA polymerase | LG Life Sciences,
S. Korea | Phase II |
| Myrcludex B | Entry Inhibition | Myr-GmbH,
Germany | Phase IA, Germany |
HAP Compound
Bay 41-4109 | Inhibits viral nucleocapsid | AiCuris, Germany | Phase I |
| REP 9AC | HBsAg Release Inhibitor | REPLICor Inc.
Montreal, Quebec | Phase I |
| Alinia (Nitazoxanide) | Small Molecule | Romark Labs
Tampa, FL | Preclinical |
| dd-RNAi compound | Gene silencing | Benitec, Australia
and Biomics, China | Preclinical |
| ARC-520 | RNAi gene silencer | Arrowhead Research, Pasadena, CA | Preclinical |
| NVR-1221 | Capsid inhibitor | Novira Therapeutics, Doylestown, PA | Preclinical |
| Non-Interferon Immune Enhancers - Boost T-cell infection-fighting immune cells and natural interferon production |
Zadaxin
(Thymosin
alpha-1) | Immune stimulator | SciClone
San Mateo, CA | Orphan drug approval in US for liver cancer |
| CYT107 (Interleukin-7) | Immunemodulator | Cytheris,
Paris, France | Phase I/IIa |
| DV-601 | HBV surface and core antigens | Dynavax,
Berkeley, CA | Phase Ib |
| HBV Core Antigen Vaccine | Therapeutic HBV vaccine | Emergent Europe, U.K. | Phase I |
| GS-9620 | TLR7 agonist | Gilead
Foster City, USA | Phase I |
| GI13000 | HBV Antigen | Globe Immune
Louisville, CO | Preclinical with Gilead |
| Post-Exposure and/or Post-Liver Transplant Treatment |
| HyperHEP S/D | HBV Immuneglobulin | Talecris
RTP, NC | FDA Approved 1977 |
| Nabi-HB | HBV Immuneglobulin | Biotest,
Boca Raton, FL | FDA Approved
1999 |
| Hepa Gam B | HBV Immuneglobulin | CangeneCanada | FDA Approved 2006 |
发表于 2013-5-1 15:33
